Rheumatology Medical News

Your Unread Messages

See All

Tracy Hampton, PhD

FDA Update

Anti-CD20 Antibody Granted Accelerated Approval for CLL

Roberta Buell, MBA
Congress Proposes SGR Fix

Dorothy J. Schirf, MD

Technology Advances

Radiosurgery Trial Sparks Optimism for Early Lung Cancer

Sara Hartley

Cancer Science

Using Embryonic Stem Cells to Test Breast Cancer Genes

See All Messages (38 new messages)

Hello, Suzanne Dixon
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effectiveness of adalimumab in treating patients with active psoriatic arthritis (PsA) and predictors of good clinical responses for arthritis, skin, and nail lesions
Annals of Rheumatic Diseases, 10/22/09

van den Bosch F et al. – Adalimumab was effective in patients with PsA. Lower impairment of physical function, greater pain, male sex, and no systemic treatment with glucocorticoids were factors that increased the chance of achieving good clinical response.

Methods

Prospective, 12-week, open-label, uncontrolled study
Patients received adalimumab 40 mg every other week in addition to standard therapy
4 definitions of good clinical response: ≥ 50% improvement in American College of Rheumatology (ACR50) response criteria, good European League Against Rheumatism (EULAR) response,≥ 3-grade improvement in Physician's Global Assessment of psoriasis (PGA), and ≥ 50% improvement in the Nail Psoriasis Severity Index (NAPSI)

Results

442 patients
94% completed 12 weeks of treatment
Week 12, 74%, 51%, and 32% of the patients achieved ACR20, 50, and 70, respectively; 87% and 61% experienced a moderate and good EULAR response, respectively
Percentage of patients with PGA "Clear/Almost Clear" increased from 34% (baseline) to 68%
Mean NAPSI reduced by 44%
No new safety signals detected
Lower Health Assessment Questionnaire Disability Index score, greater pain assessment, male sex, and absence of systemic glucocorticoid therapy strongly associated with achievement of ACR50 and good EULAR response
Greater CRP concentration and polyarthritis predicted ACR50, and noninvolvement of large joints predicted good EULAR response

<< Previous
Lymphoma in patients treated with anti-TNF. Results of the 3-year...

Next >>
Novel expression signatures identified by transcriptional...